S12 - Progressive Multiple Sclerosis
| Event Time: | Monday May 6, 2019 1:00 pm to 3:00 pm |
| Topic(s): | MS and CNS Inflammatory Disease |
| Director(s): | |
| Description: | |
| Completion Message: | |
| CME Credits: | 2 |
| Core Competencies: |
| Start/End Time | Title | Faculty |
|---|---|---|
| 2:40 PM - 3:00 PM | Q&A Panel with Authors | Faculty |
| Speaker | Disclosure |
|---|
| Start Time | Pub. | Title | Presenter |
|---|---|---|---|
| 1:00 PM | 001 | Accelerated Cord Atrophy Precedes Conversion to Secondary Progressive Disease in Relapsing Multiple Sclerosis |
Disclosure: Dr. Bischof has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen Idec, Actelion.
|
| 1:00 PM | 002 | A Mouse Model of Meningeal Inflammation and Subpial Demyelination Identifies an IL-17-mediated Mechanism of Cortical Injury that is Inhibited by Siponimod Therapy |
Disclosure: Dr. Ramaglia has received research support from Novartis.
|
| 1:00 PM | 003 | Microglial Activation in the Deep Grey Matter is Associated with Regional Atrophy and Physical Disability in Multiple Sclerosis |
Disclosure: Dr. Singhal has nothing to disclose.
|
| 1:00 PM | 004 | Atrophied T2 lesion volume is Associated with Disability Progression and Conversion to Secondary-Progressive Multiple Sclerosis |
Disclosure: Dr. Zivadinov has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Teva Pharmaceuticals, Biogen Idec, Genzyme-Sanofi, Novartis, Claret Medical and EMD Serono. Dr. Zivadinov has received personal compensation in an editorial capacity for BMC Neurolog. Dr. Zivadinov has received research support from Teva Pharmaceuticals, Biogen Idec, Genzyme-Sanofi, Novartis, Claret Medical and EMD Serono.
|
| 1:00 PM | 005 | Axonal Integrity in Primary and Secondary Progressive Multiple Sclerosis: a Baseline Subgroup Analysis of Sex, Age, and Disease Severity from the Phase III SPI2 Study |
Disclosure: Dr. Narayanan has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with NeuroRx Research and Novartis Canada.
|
| 1:00 PM | 006 | A Novel Functional Composite Endpoint to Characterize Disease Progression in Patients with Secondary Progressive Multiple Sclerosis |
Disclosure: Dr. Kappos has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with received in the last 3 years and used exclusively for research support at the Department: steering committee, advisory board and consultancy fees from Actelion, Alkermes, Almirall, Bayer, Biogen, Celgene/Receptos, df-mp, Excemed, GeNeuro SA, Genzyme, Japan Tobacco, Merck, Minoryx, Mitsubishi Pharma, Novartis, Roche, sanofi-aventis, Santhera, Teva, Vianex and royalties for Neurostatus-UHB products. . Dr. Kappos has received research support from The Research of the MS Center in Basel has been supported by grants from Bayer, Biogen, Novartis, the Swiss MS Society, the Swiss National Research Foundation, the European Union and Roche Research Foundations.
|
| 1:00 PM | 007 | Response to Treatment According to Progressive Disease Type: Analysis from a Phase II Progressive MS Trial of Ibudilast |
Disclosure: Dr. Goodman has received personal compensation for consulting serving on a scientific advisory board speaking or other activities with EMD-Serono and Teva. Dr. Goodman has received research support from Atara Biogen Roche Sanofi-Genzyme Novartis Sun Pharma and Teva.
|
| 1:00 PM | 008 | Natalizumab Reduces Serum Concentrations of Neurofilament Light Chain in Secondary Progressive Multiple Sclerosis Patients From the Phase 3 ASCEND Study |
Disclosure: Dr. Kapoor has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Actelion, Biogen, Sanofi Genzyme, Novartis Pharmaceuticals, Roche, and Teva. Dr. Kapoor has received research support from UK National Institute of Health Research UCL/H Biomedical Research Centre.
|
| 1:00 PM | 009 | The Predictive Value of Neurofilament Light Chain Levels in Blood for Cognitive Impairment in Patients with Secondary Progressive Multiple Sclerosis |
Disclosure: Dr. Kuhle has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Scientific advisory boards for Novartis Pharmaceuticals, Merck, Biogen, Sanofi Genzyme, Roche and Bayer. Funding for travel and/or speaker honoraria from Biogen, Sanofi Genzyme, Novartis, Merck Serono, Roche, Teva and the Swiss MS Society.. Dr. Kuhle has received research support from Consulting fees from Biogen, Novartis, Protagen AG, Roche, Teva; speaker fees from the Swiss MS Society, Biogen, Novartis, Roche, Genzyme; travel expenses from Merck Serono, Novartis, Roche; grants from ECTRIMS Research Fellowship Programme, University of Basel, Swiss MS Society, Swiss National Research Foundation (320030_160221), Bayer AG, Biogen, Genzyme, Merck, Novartis, Roche.
|
Ready to register for the 2019 AAN Annual Meeting?
Related Courses
| 7:00 AM-9:00 AM |
|---|
|
C7 -
Clinical Pearls in Autoimmune Neurology: Real World Cases
Stacey Clardy MD, PhD |
| 9:30 AM-11:30 AM |
|
C19 -
Multiple Sclerosis Overview I: Clinical Pearls
Mary Willis MD |
| 1:30 PM-3:30 PM |
|
C29 -
Multiple Sclerosis Overview II: Clinical Advances
Scott Newsome DO, FAAN |
| 7:00 AM-9:00 AM |
|---|
|
C44 -
Multiple Sclerosis Therapy: Symptom Management
Andrew Solomon MD, FAAN |
| 9:15 AM-12:00 PM |
|
Presidential Plenary Session
Natalia Rost MD, MPH, FAAN, FAHA |
| 11:30 AM-6:30 PM |
|
P1 -
Poster Session 1
|
| 1:00 PM-3:00 PM |
|
C49 -
Neurology Update I: Multiple Sclerosis, Sleep, and Neuromuscular Disease
Ralph Jozefowicz MD, FAAN, Adam Quick MD |
|
C56 -
Multiple Sclerosis Therapy: Disease-modifying Treatment I
Scott Newsome DO, FAAN |
|
S6 -
MS and CNS Inflammatory Disease: Clinical Considerations I
|
| 3:30 PM-5:30 PM |
|
C73 -
Multiple Sclerosis Therapy: Disease-modifying Treatment II
John Rose MD, FAAN |
| 7:00 AM-9:00 AM |
|---|
|
C86 -
Neuromyelitis Optica Spectrum Disorders
Dean Wingerchuk MD, FAAN |
| 9:15 AM-12:00 PM |
|
Contemporary Clinical Issues Plenary Session
Randolph Marshall MD, FAAN |
| 11:30 AM-6:30 PM |
|
P2 -
Poster Session 2
|
| 1:00 PM-3:00 PM |
|
C100 -
Esclerosis Múltiple y Otras Enfermedades Inflamatorias Desmielinizantes y Autoinmunes del Sistema Nervioso Central (MS and Other Demyelinating Inflammatory and Autoimmune Central Nervous System Disorders)
Lilyana Amezcua MD, FAAN |
| 3:30 PM-5:30 PM |
|
S19 -
Child Neurology: Updates in Autism, Migraine, MS, and Stroke
|
| 7:00 AM-9:00 AM |
|---|
|
C130 -
Diagnostic Pearls in Myelitis: a Case-based Approach
Eoin Flanagan MBBCh |
| 9:15 AM-11:30 AM |
|
Clinical Trials Plenary Session
Deborah Hall MD, PhD, FAAN, Holly Hinson MD, MCR, FAAN |
| 11:30 AM-6:30 PM |
|
P3 -
Poster Session 3
|
| 1:00 PM-3:00 PM |
|
C142 -
Autoimmune Neurology I Basics and Beyond: Autoimmune Encephalitis and Paraneoplastic Neurological Syndromes of the CNS and PNS
Stacey Clardy MD, PhD |
|
N3 -
Neuroscience in the Clinic: Stem Cells
Paul George MD, PhD, MSE, Antonio Omuro MD |
|
S26 -
MS and CNS Inflammatory Disease: Clinical Considerations II
|
| 3:30 PM-5:30 PM |
|
C160 -
Autoimmune Neurology II Advanced: Autoimmune Encephalitis at the Frontiers of Neuroscience
Eoin Flanagan MBBCh |
|
S31 -
MS and CNS Inflammatory Disease: Imaging
|
| 9:15 AM-11:30 AM |
|---|
|
Frontiers in Neuroscience Plenary Session
Paul George MD, PhD, MSE |
| 11:30 AM-6:30 PM |
|
P4 -
Poster Session 4
|
| 1:00 PM-3:00 PM |
|
C181 -
Treatment of Pediatric Multiple Sclerosis in the Current Era
Brenda Banwell MD, FAAN |
|
S37 -
MS Biomarkers
|
| 3:30 PM-5:30 PM |
|
Presentation of the John Dystel Prize for Multiple Sclerosis Research
|
| 3:45 PM-4:15 PM |
|
Update on the Complementary Therapies for MS: An Evidence-based Review
Vijayshree Yadav MD, FAAN |
| 11:30 AM-6:30 PM |
|---|
|
P5 -
Poster Session 5
|
| 12:00 PM-12:45 PM |
|
A "How to and Why" of the Shared Medical Appointments: A Way to Meet the Needs of the Patient and Provider While Maximizing Clinical Time
Mary Rensel MD, FAAN, Nancy Isenberg MD, MPH, FAAN |
| 1:00 PM-3:00 PM |
|
C226 -
Neuro-rheumatology: Neurological Manifestations of Systemic Inflammatory and Autoimmune Disease I
Jeffrey Gelfand MD, MAS, FAAN |
|
S49 -
MS Epidemiology and Risk Stratification
|
| 3:30 PM-5:30 PM |
|
C236 -
Neuro-rheumatology: Neurological Manifestations of Systemic Inflammatory and Autoimmune Disease II
Jeffrey Gelfand MD, MAS, FAAN |
|
S55 -
MS Basic Science
|
| 7:00 AM-9:00 AM |
|---|
|
C248 -
Multiple Sclerosis in the Trenches: Controversy and Consensus in Clinical Decision-Making
Aaron Miller MD, FAAN |
| 9:15 AM-11:30 AM |
|
Neurology Year in Review Plenary Session
Martinson Arnan MD |
| 1:00 PM-3:00 PM |
|
S56 -
MS Trials and Treatment
|
| 3:30 PM-4:30 PM |
|
C257 -
Education Blitz: Evolution of Autoimmune Neurology
Steven Vernino MD, PhD, FAAN |
|
C258 -
Education Blitz: Multiple Sclerosis
Stephen Krieger MD, FAAN |